Published in AIDS Weekly, January 8th, 2001
HE2000 is the lead investigational compound in a new class of immune regulating hormones and hormone analogs being developed by Hollis-Eden. Data presented are from an interim analysis of 37 patients through three treatment courses in the company's Phase I/II South African clinical trial in treatment-naive HIV patients.
Highlights of the results include statistically significant increases throughout the five-month treatment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.